ERCC1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using ERCC1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of A549 cells using ERCC1 mouse mAb (green) and negative control (red).    

  
  

ERCC1 (Excision Repair Cross-Complementation Group 1) is a critical protein involved in the nucleotide excision repair (NER) pathway, which repairs DNA damage caused by UV radiation, environmental carcinogens, and platinum-based chemotherapeutic agents. The ERCC1 protein forms a heterodimer with XPF (xeroderma pigmentosum group F) to catalyze the incision of damaged DNA strands during NER. Due to its role in DNA repair, ERCC1 has been extensively studied as a potential biomarker for predicting resistance to platinum-based chemotherapy (e.g., cisplatin, oxaliplatin) in cancers such as colorectal, lung, and ovarian cancer.

ERCC1 antibodies are widely used in research and clinical settings to detect ERCC1 protein expression levels, typically via immunohistochemistry (IHC) or immunoblotting. High ERCC1 expression has been associated with poor therapeutic response, as enhanced DNA repair capacity may reduce the efficacy of DNA-damaging agents. However, clinical utility remains controversial due to variability in antibody specificity, assay standardization, and conflicting study outcomes. Notably, some ERCC1 antibodies (e.g., clone 8F1) cross-react with non-functional ERCC1 isoforms or unrelated proteins, complicating data interpretation. Recent efforts focus on validating antibodies (e.g., clone 4F9) with higher specificity for the functional ERCC1-XPF complex. Despite challenges, ERCC1 antibody-based assays continue to inform studies exploring personalized cancer treatment strategies and mechanisms of chemoresistance. Ongoing research aims to refine detection methods and integrate ERCC1 with other biomarkers for improved predictive accuracy.